Kura Oncology Inc
NASDAQ:KURA 4:00:00 PM EDT
| Market Cap (Intraday) | 508.33M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.90 |
| 50-Day MA | $6.17 |
| 200-Day MA | $10.23 |
Kura Oncology Inc Stock, NASDAQ:KURA
12730 High Bluff Drive, Suite 400, San Diego, California 92130
United States of America
Phone: +1.858.500.8800
Number of Employees: 192
Description
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.